These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 1710485)
1. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. O'Reilly SE; Hoskins P; Klimo P; Connors JM Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485 [TBL] [Abstract][Full Text] [Related]
2. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058 [TBL] [Abstract][Full Text] [Related]
3. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442 [TBL] [Abstract][Full Text] [Related]
4. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma. Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801 [TBL] [Abstract][Full Text] [Related]
5. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718 [TBL] [Abstract][Full Text] [Related]
6. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors. Pichert G; Peters J; Stahel RA; Dommann C; Joss R; Gebbers JO; Kroner T; Sulser H; Honegger HP; Maurer R Ann Oncol; 1992 Sep; 3(8):645-9. PubMed ID: 1280460 [TBL] [Abstract][Full Text] [Related]
9. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460 [TBL] [Abstract][Full Text] [Related]
10. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
11. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179 [TBL] [Abstract][Full Text] [Related]
12. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk KP; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M Blood; 1998 Dec; 92(12):4560-7. PubMed ID: 9845521 [TBL] [Abstract][Full Text] [Related]
14. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma. Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759 [TBL] [Abstract][Full Text] [Related]
15. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas. Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617 [TBL] [Abstract][Full Text] [Related]
16. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863 [TBL] [Abstract][Full Text] [Related]
17. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas]. Krieger G; Kreysing E; Kneba M Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M; N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384 [TBL] [Abstract][Full Text] [Related]
19. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577 [TBL] [Abstract][Full Text] [Related]
20. [The treatment of large-cell non-Hodgkin's lymphomas with the MACOP-B protocol]. Montalbán C; Rodríguez García JL; Marcos Robles J; Serrano M; Arechaga S; Perales J; Bellas C Med Clin (Barc); 1991 Oct; 97(14):521-5. PubMed ID: 1721672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]